申请人:Nikken Chemicals Company, Limited
公开号:EP0995752A1
公开(公告)日:2000-04-26
A triazolo-1,4-diazepine compound having the formula (I):
wherein A represents CO, CO-B, or B, B represents a C1 to C6 alkylene group or a C2 to C6 alkylene group having an oxygen atom interposed in the middle thereof, X represents N-O or CH, n represents an integer of 2 to 6, R represents a hydroxyl group, a C1 to C6 lower alkyloxy group or a C1 to C6 lower alkylamino group, provided that these groups may be substituted with an N,N-dimethylamino group, an N,N-diethylamino group, a phenyl group, or a heterocyclic group, and R1 represents a hydrogen atom or a C1 to C3 lower alkyl group having both a PAF antogonistic action and a thromboxane synthesis inhibiting action, and a pharmaceutical composition containing the same as an active ingredient.
一种具有式 (I) 的三唑并-1,4-二氮杂卓化合物:
其中 A 代表 CO、CO-B 或 B,B 代表 C1 至 C6 亚烷基或中间含有一个氧原子的 C2 至 C6 亚烷基,X 代表 N-O 或 CH,n 代表 2 至 6 的整数,R 代表羟基、C1 至 C6 低级烷氧基或 C1 至 C6 低级烷基氨基、但这些基团可被 N,N-二甲基氨基基团、N,N-二乙基氨基基团、苯基或杂环基团取代,R1 代表氢原子或同时具有 PAF 拮抗作用和血栓素合成抑制作用的 C1 至 C3 低级烷基,以及含有这些基团作为活性成分的药物组合物。